Trade APUS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Apimeds Pharmaceuticals US, Inc. (APUS) is trading at US$4.59, up 42.55% today as of Oct 5, 16:00 EDT. The company has a market capitalisation of US$7.3M. Over the past 52 weeks, APUS has traded between US$0.61 and US$17.90. On Syfe you can trade APUS with $0 commission and add it to your watchlist.
| Previous close | US$3.22 |
|---|---|
| Market cap | US$7.3M |
| 52-week range | US$0.61 – US$17.90 |
| Volume | 33.43M |
| Exchange | US |
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.
Year: 2025
Apimeds Pharmaceuticals US, Inc. (APUS) stock is trading at US$4.59, +42.55% from the previous close of US$3.22.
The market cap for Apimeds Pharmaceuticals US, Inc. (APUS) stock is approximately US$7.3M.
The 52-week high for Apimeds Pharmaceuticals US, Inc. (APUS) stock is US$17.90.
The 52-week low for Apimeds Pharmaceuticals US, Inc. (APUS) stock is US$0.61.
Apimeds Pharmaceuticals US, Inc. (APUS) does not currently pay a dividend.
Stay on top of APUS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
